3 strong blue chip ASX 200 shares to buy

These blue chip have been rated as buys…

| More on:
a man looks down at his phone with a look of happy surprise on his face as though he is thrilled with good news.

Image source: Getty Images

If you’re wanting to build a strong portfolio, then having a few blue chips in there could be a good starting point.

Blue chips are typically large companies that have been operating for many years, have stable cash flows, and experienced management teams. This can make them lower risk options and a good foundation to build a portfolio from.

But which blue chip ASX 200 shares could be in the buy zone? Here are three to consider:

CSL Limited (ASX: CSL)

The first blue chip ASX 200 share to consider is CSL. It is one of the world’s leading biotechnology companies, comprising the CSL Behring business and the Seqirus business. It appears well-placed for growth over the long term thanks to strong demand for its immunoglobulins and its lucrative research and development pipeline. Macquarie is a fan of the company and has an outperform rating and $338.00 price target

Goodman Group (ASX: GMG)

Another blue chip ASX 200 share to look at is Goodman Group. It is a leading integrated commercial and industrial property company that has been growing at a solid rate over the last decade. This has been driven by the overwhelming success of its strategy of developing high quality industrial properties in strategic locations, close to large urban populations and in and around major gateway cities globally. The team at Citi appear confident this strategy will underpin further strong growth in the years to come. Its analysts have a buy rating and $27.50 price target on its shares.

ResMed Inc. (ASX: RMD)

A final blue chip ASX 200 share to look at is ResMed. It is a sleep treatment-focused medical device company with a portfolio of industry-leading products improving the lives of sufferers of conditions such as sleep apnoea. The good news is that this is a huge market with just an estimated one fifth of sufferers currently diagnosed. This gives ResMed a long runway for growth in the future. Credit Suisse is positive on ResMed. It has an outperform rating and $43.00 price target on the company’s shares.

Should you invest $1,000 in CSL right now?

Before you consider CSL, you'll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and CSL wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of January 13th 2022

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Blue Chip Shares